In the present study, we observed that isorhamnetin attenuated fat droplets and improved liver morphology in DIO mice in a similar fashion to other PPARγ antagonists, suggesting that isorhamnetin can be used to prevent hepatic steatosis. Here, PPARG is linked to fatty liver disease.